Home  »  Companies   »  Selected Notes From Wall Street Analysts On Altimm...

Selected Notes From Wall Street Analysts On Altimmune, Inc. (ALT)

On Tuesday, shares of Altimmune, Inc. (NASDAQ:ALT) marked $14.22 per share versus a previous $12.60 closing price. With having a 12.86% gain, an insight into the fundamental values of Altimmune, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. ALT showed a rise of 652.38% within its YTD performance, with highs and lows between $1.51 – $35.10 during the period of 52 weeks, compared to the simple moving average of 51.35% in the period of the last 200 days.

B. Riley FBR equity researchers changed the status of Altimmune, Inc. (NASDAQ: ALT) shares to a “Buy” rating in the report published on September 25th, 2020. Other analysts, including Evercore ISI, also published their reports on ALT shares. Evercore ISI repeated the rating from the previous report, marking ALT under “Outperform” rating, in the report published on August 14th, 2020. Additionally, ALT shares got another “Overweight” rating from Piper Sandler, setting a target price of $80 on the company’s shares, according to the report published in July 31st, 2020. On July 28th, 2020, JMP Securities Initiated an Mkt Outperform rating and increased its price target to $50. On the other hand, ROTH Capital Resumed the “Buy” rating for ALT shares, as published in the report on February 24th, 2020. ROTH Capital seems to be going bullish on the price of ALT shares, based on the price prediction for ALT, indicating that the shares will jump to $8.30, giving the shares “Buy” rating based on their report from July 19th, 2019. Another “Overweight” rating came from Piper Jaffray, providing a prediction for $8.30 price target according to the report published in October 9th, 2017.

[bold-text]Altimmune, Inc. (ALT) Analysis[/bold-text]

The present dividend yield for ALT owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -56.30%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of Altimmune, Inc. (ALT) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of -66.00% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 17.90 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while ALT is currently recording an average of 2.31M in volumes. The volatility of the stock on monthly basis is set at 9.94%, while the weekly volatility levels are marked at 9.95%with 4.25% of gain in the last seven days.

[bold-text]What to Look for When Analyzing Altimmune, Inc. Shares?[/bold-text]

Altimmune, Inc. (ALT) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare ALT shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Altimmune, Inc., while the value 3.85 can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -2.21 is supported by the yearly EPS growth of 89.50%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 6.20%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 45.90% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

[bold-text]Are Institutional Investors Increasing Stakes in ALT Shares?[/bold-text]

It appears that more than several institutional investors and hedge funds decided to increase stakes in ALT in the recent period. That is how VHCP Management LLC now has an increase position in ALT by — in the first quarter, owning 4.5 million shares of ALT stocks, with the value of $59.4 million after the purchase of an additional 4,500,000 shares during the last quarter. In the meanwhile, Baker Bros. Advisors LP also increased their stake in ALT shares changed — in the first quarter, which means that the company now owns 2.11 million shares of company, all valued at $27.82 million after the acquisition of additional 2,107,600 shares during the last quarter.

D. E. Shaw & Co. LP acquired a new position in Altimmune, Inc. during the first quarter, with the value of $21.87 million, and Renaissance Technologies LLC increased their stake in the company’s shares by 50.03% in the first quarter, now owning 308,700 shares valued at $12.22 million after the acquisition of the additional 925707 shares during the last quarter. In the end, Hudson Bay Capital Management LP increased their position by 2.97% during the first quarter, now owning 780000 ALT shares, now holding the value of $10.3 million in ALT with the purchase of the additional 780,000 shares during the period of the last quarter. At the present, 45.90% of ALT shares are in the ownership of institutional investors.

Leave a Comment

Your email address will not be published.

Related Posts